Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
Open Access
- 19 August 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 6 (1), 31629
- https://doi.org/10.1038/srep31629
Abstract
Middle East Respiratory Syndrome coronavirus (MERS-CoV) has repeatedly caused outbreaks in the Arabian Peninsula. To date, no approved medical countermeasures (MCM) are available to combat MERS-CoV infections. Several neutralizing human monoclonal antibodies (mAbs), including m336, a germline-like human mAb, have been chosen as promising MCM for MERS-CoV. However, their clinical development has been hindered by the lack of a robust animal model that recapitulate the morbidity and mortality of human infections. We assessed the prophylactic and therapeutic efficacy of m336 by using well-characterized transgenic mice shown to be highly sensitive to MERS-CoV infection and disease. We found that mice treated with m336 prior to or post lethal MERS-CoV challenging were fully protected, compared to control mice which sufferered from profound weight loss and uniform death within days after infection. Taken together, these results support further development of m336 and other human monoclonal antibodies as potential therapeutics for MERS-CoV infection.This publication has 47 references indexed in Scilit:
- Middle East Respiratory Syndrome Coronavirus in Bats, Saudi ArabiaEmerging Infectious Diseases, 2013
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in HumansmBio, 2012
- Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5Emerging Microbes & Infections, 2012
- Prophylaxis and Therapy for Chikungunya Virus InfectionThe Journal of Infectious Diseases, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- The growth and potential of human antiviral monoclonal antibody therapeuticsNature Biotechnology, 2007
- Comparative Analysis of Twelve Genomes of Three Novel Group 2c and Group 2d Coronaviruses Reveals Unique Group and Subgroup FeaturesJournal of Virology, 2007
- Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus ReceptorJournal of Virology, 2007
- Passive Immunity in Prevention and Treatment of Infectious DiseasesClinical Microbiology Reviews, 2000